Helicobacter pylori-positive patients with pruritic skin diseases are at increased risk for gastric cancer

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 1, 2004, Pages 80-84

  Shiotani, A ^a,c   Sakurane, M ^b   Furukawa, F ^b  

^a WAKAYAMA UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY;

ADULT; AGED; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CHRONIC URTICARIA; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; NUMMULAR DERMATITIS; PAPULAR URTICARIA; PRIORITY JOURNAL; PRURIGO; PRURITUS; STOMACH CANCER;

EID: 4344578298     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01977.x     Document Type: Conference Paper

References (38)

1. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-5.
2. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989; 96: 614-25.
3. Working Party of the European Helicobacter pylori Study Group. Guidelines for clinical trials in Helicobacter pylori infection. Gut 1997; 41(Suppl. 2): S1-S9.
4. Shiotani A, Nurgalieva ZZ, Yamaoka Y, Graham DY. Helicobacter pylori. Med Clin North Am 2000; 84: 1125-36.
5. Cheli R, Crespi M, Testino G, Citarda F. Gastric cancer and Helicobacter pylori: biologic and epidemiologic inconsistencies. J Clin Gastroenterol 1998; 26: 3-6.
6. Davis PA, Sano T. The difference in gastric cancer between Japan, USA and Europe: what are the facts? What are the suggestions? Crit Rev Oncol Hematol 2001; 40: 77-94.
7. Shiotani A, Okada K, Yanaoka K, et al. Beneficial effect of Helicobacter pylori eradication in dermatologic diseases. Helicobacter 2001; 6: 60-5.
8. Shiotani A. Linking Helicobacter pylori and chronic bronchitis: fact or fancy? J Gastroenterol 2002; 37: 402-3.
9. Di Campli C, Gasbarrini A, Nucera E, et al. Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci 1998; 43: 1226-9.
10. Gasbarrini A, Franceschi F, Gasbarrini G, Pola P. Extraintestinal pathology associated with Helicobacter infection. Eur J Gasatroenterol Hepatol 1997; 9: 231-3.
11. Gasbarrini A, Serricchio M, Tondi P, Gasbarrini G, Pola P. Association of Helicobacter pylori infection with primary Raynaud phenomenon. Lancet 1996; 348: (Letter) 966-7.
12. Kohda K, Kuga T, Kogawa K, et al. Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol 2002; 118: 584-8.
13. Leontiadis GI. Sharma VK, Howden CW. Non-gastrointestinal tract associations of Helicobacter pylori infection. Arch Intern Med 1999; 159: 925-40.
14. Realdi G, Dore MP, Fastame L. Extradigestive manifestations of Helicobacter pylori infection. Fact or fiction? Dig Dis Sci 1999; 44: 229-36.
15. Bolero F. Pruritus as a manifestation of systemic disorders. Cutis 1978; 21: 873-80.
16. Klecz RJ, Schwartz RA. Pruritus. Am Fam Physician 1992; 45: 2681-6.
17. Zirwas MJ, Seraly MP. Pruritus of unknown origin: a retrospective study. J Am Acad Dermatol 2001; 45: 892-6.
18. Cormia FE. Pruritus, an uncommon but important symptom of systemic carcinoma. Arch Dermatol 1965; 92: 36-9.
19. Krajnik M, Zylicz Z. Pruritus in advanced internal diseases. Pathogenesis and treatment. Neth J Med 2001; 58: 27-40.
20. Funaki M, Ohno T, Dekio S, et al. Prurigo nodularis associated with advanced gastric cancer: report of a case. J Dermatol 1996; 23: 703-7.
21. Shoenfeld Y, Weiberger A, Ben-Bassat M, Pinkhas J. Generalized pruritus in metastatic adenocarcinoma of the stomach. Dermatologica 1977; 155: 122-4.
22. Higgins EM, du Vivier AW. Cutaneous manifestations of malignant disease. Br J Hosp Med 1992; 48: 58-61.
23. Lomholt H, Thestrup-Pedersen K. Paraneoplastic skin manifestations of lung cancer. Acta Derm Venereol 2000; 80: 200-2.
24. Moschella SL. Cutaneous manifestations of internal malignancy. Med Clin North Am 1975; 59: 471-9.
25. Poole S, Fenske NA. Cutaneous markers of internal malignancy. II. Paraneoplastic dermatoses and environmental carcinogens. J Am Acad Dermatol 1993; 28 (2. Part 1): 147-64.
26. Poole S, Fenske NA. Cutaneous markers of internal malignancy. I. Malignant involvement of the skin and the genodermatoses. J Am Acad Dermatol 1993; 28: 1-13.
27. Rosenberg FW. Cutaneous manifestations of internal malignancy. Cutis 1977; 20: 227-34.
28. Shelley WB. Cutaneous signs of internal malignancy. Minn Med 1974; 57: 773-9.
29. Wallach PM, Flannery MT, Stewart JM. Paraneoplastic syndromes for the primary care physician. Prim Care 1992; 19: 727-46.
30. Muramatsu T, Iida T, Tada H, et al. Bullous pemphigoid associated with internal malignancies: identification of 180-kDa antigen by western immunoblotting. Br J Dermatol 1996; 135: 782-4.
31. Ogawa H, Sakuma M, Morioka S, et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci 1995; 9: 136-41.
32. Sano T, Sasako M, Kinoshita T, Maruyama K. Links Recurrence of early gastric cancer. Follow-up of 1475 patients and review of the Japanese literature. Cancer 1993; 72: 3174-8.
33. Kitauchi S, Oohata H, Yosikawa A. et al. High-risk population for stomach cancer detected by serum pepsinogen and antibodies to H. pylori. Gastroenterol 2001; 120 (Suppl. 1): A3074.
34. Rosenberg FW. Cutaneous manifestations of internal malignancy. Cutis 1977; 20: 227-34.
35. Krajnik M, Zylicz Z. Pruritus in advanced internal diseases. Pathogenesis and treatment. Neth J Med 2001; 58: 27-40.
36. Tatsuta M, Iishi H, Baba M, Taniguchi H. Enhanced induction of gastric carcinogenesis by N-methyl-N-nitro-N-nitrosoguanidine in deoxycorticosterone acetate-NaCl hypertensive rats and its inhibition by potassium chloride. Cancer Res 1991; 51: 2863-6.
37. Simile M, De Miglio M, Calvisi D, et al. Long-term dehydroepiandrosterone and 16alpha-fluoro-5-androsten-17-one administration enhances DNA synthesis and induces expression of c-fos and c-Ha-ras in a selected population of preneoplastic lesions in liver of diethylnitrosamine-initiated rats. Carcinogenesis 2001; 22: 301-8.
38. Gordon GB, Helzlsouer KJ, Alberg AJ, Comstock GW. Serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate and the risk of developing gastric cancer. Cancer Epidemiol Biomarkers Prev 1993; 2: 33-5.